Patent focus on agents for atherosclerosis: September 1999 - February 2000

Bibliography

• MATSUDA K: ACAT inhibitors as anti-atheroscleroticagents: compounds and mechanisms. Med. Res. Rev. (1994) 14:271–305.
   PubMed Web of Science ®Google Scholar
• SLISKOVIC DR, TRIVEDI BK: ACAT Inhibitors: potentialanti-atherosclerotic agents. Curr. Med. Chem. (1994) 1:204–225.
   Google Scholar
• BILLER SA, NEUENSCHWANDER K, PONPIPOM MM et al.:Squalene synthase inhibitors. Curr. Pharm. Des. (1996) 2(1):1–40.
   Web of Science ®Google Scholar
• HARRITY TW, GEORGE RJ, CIOSEK CP: BMS-188494, anorally active squalene synthetase inhibitor which lowers cholesterol in animals. In: Twelfth International Symposium on Drugs Affecting Lipid Metabolism. (1995) Houston, Texas, USA.
   Google Scholar
• DICKSON JK, BILLER SA, MAGNIN DR et al.: Orally activesqualene synthetase inhibitors: bis((acyloxy)alkyl) prodrugs of the a-phosphosulfonic acid moiety. J. Med. Chem. (1996) 39:661–664.
   PubMed Web of Science ®Google Scholar
• GOTTELAND J-P, DELHON A, OMS P et al.: Design andsynthesis of new hypocholesterolemic organosilanes with antioxidant properties. Bioorg. Med. Chem. Lett. (1996) 6(5):533–538.
   Web of Science ®Google Scholar
• INTERNATIONAL LIPID INFORMATION BUREAU: Bloodlipids and coronary heart disease. In: The RIB Lipid Handbook for Clinical Practice. (1995) Morris Plains, New Jersey, USA.
   Google Scholar
• PATSCH W, GOTTO AM: High-density lipoproteincholesterol, plasma triglyceride and coronary heart disease: pathophysiology and management. Adv. Pharmacol. (1995) 32:375–426.
   PubMedGoogle Scholar
• NATIONAL CHOLESTEROL EDUCATION PROGRAM:expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II). Second report of the National Cholesterol Education Program (NCEP). Circulation (1994) 89:1329–1445.
   Google Scholar
• STAELS B, AUWERX J: Role of PPAR in the pharmacol-ogical regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharm. Des. (1997) 3:1–14.
   Web of Science ®Google Scholar
• WILLSON TM, BROWN PJ, STERNBACH DD et al.: The: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43(4):527–550.
   PubMed Web of Science ®Google Scholar
• ••Timely and thorough review of the PPARs, their knownfunctions and their natural and synthetic ligands.
   Google Scholar
• HARWOOD HJ, HAMANAKA ES: Modulators of dislipi-. Emerging Drugs (1998) 3:147.
   Google Scholar
• •Useful review of new therapeutic agents with anti-atherosclerosis potential.
   Google Scholar
• SPIEGELMAN BM: PPAR-y: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 47:507–514.
   PubMed Web of Science ®Google Scholar
• HULIN B, MCCARTHY PA, GIBBS EM: The glitazone family of antidiabetic drugs. Curr. Pharm. Des. (1996) 2:85–102.
   Web of Science ®Google Scholar
• DE WINTHER MPJ, VAN DIJK KW, HAVEKES LM et al.:Macrophage scavenger receptor class A: a multifunc-tional receptor in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (2000) 20(2):290–297.
   PubMed Web of Science ®Google Scholar
• •A useful review of this emerging target.
   Google Scholar
• SCHMITZ G, ORSO E, ROTHE G et al: Scavenging, signal-ling and adhesion coupling in macrophages: implica-tions for atherosclerosis. Curr. Opin. Lipidology (1997) 8(5)287–300.
   Google Scholar
• WETTERAU JR, GORDON DA: The role of microsomal triglyceride transfer protein in the assembly and secretion of plasma lipoproteins. Adv. Vasc. Biol. (1999) 5:187–202.
   Google Scholar
• UTERMANN G: The mysteries of lipoprotein(a). Science (1989) 246:904–910.
   PubMed Web of Science ®Google Scholar
• SCHAEFER EJ, LAMON-FAVA S, JENNER JL et al.: Lipopro-tein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. J. Am. Med. Ass. (1994) 271:999–1003.
   Google Scholar
• WILLIAMS KJ, TABAS I: The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidology (1998) 9(5):471–474.
   PubMed Web of Science ®Google Scholar
• BOREN J, OLIN K, LEE I et al.: Identification of the principal proteoglycan-binding site in LDL: a single-point mutation in apo-B100 severely affects proteo-glycan interaction without affecting LDL receptor binding. J. Clin. Invest. (1998) 101(12):2658–2664.
   PubMed Web of Science ®Google Scholar
• GU L, OKADA Y, CLINTON SK et al.: Absence of monocyte chemoattractant protein-1 reduces athero-sclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell (1998) 2(2):275–281.
   PubMed Web of Science ®Google Scholar
• LIBBY P, SUKHOVA G, LEE RT et al.: Cytokines regulate vascular functions related to stability of the athero-sclerotic plaque. J. Cardiovasc. Pharmacol. (1995) 25 (Suppl. 2):S9–512.
   Google Scholar
• REAPE TJ, GROOT PHE: Chemokines and atheroscle-rosis. Atherosclerosis (1999) 147(2)213–225.
   Google Scholar
• ••A comprehensive and well-referenced review of the role ofchemokines in atherosclerosis, in particular aspects concerning vascular remodelling and plaque stability.
   Google Scholar
• HAKKINEN T, LUOMA JS, HILTUNEN MO et al.: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. (1999) 19(12):2909–2917.
   PubMed Web of Science ®Google Scholar
• HERSCHMAN HR: Prostaglandin synthase 2. Biochim.Biophys. Acta (1996) 1299(1):125–140.
   PubMed Web of Science ®Google Scholar
• MURPHY, JF, BORDET, J-C, WYLER, B et al.: Thevitronectin receptor (ccv83) is implicated, in coopera-tion with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem. J. (1994) 304(2):537–542.
   PubMedGoogle Scholar
• SHIH PT, BRENNAN M-L, VORA DK et al. Blocking very antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ. Res. (1999) 84(3):345–351.
   PubMed Web of Science ®Google Scholar
• STEPHENS NG, PARSONS A, SCHOFIELD PM et al.:Randomized controlled trial of effect of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant study (CHAOS). Lancet (1996) 347:781–786.
   PubMed Web of Science ®Google Scholar
• DUNNE M: WIZARD and the design of trials for secondary prevention of atherosclerosis with antibi-otics. Am. Heart J. (1999) 138(5 Pt. 2):S542–5544.
   Google Scholar
• MLOT C: Chlamydia linked to atherosclerosis. Science(1996) 272:5267.
   Web of Science ®Google Scholar
• KAJANDER EO, NEVA C: Nanobacteria: an alternativemechanism for pathogenic intra- and extracellular calcification and stone formation. Proc. Natl. Acad. Sci. USA (1998) 95(14):8274–8279.
   PubMed Web of Science ®Google Scholar
• •An interesting primer on this new and potentially important class of infectious agents.
   Google Scholar